At present, a prospectively validated treatment for SMZL is lacking. Despite this fact, splenectomy is still deemed to be the best choice for patients requiring treatment. Nevertheless, the high fraction of patients achieving a clinical response following splenectomy eventually relapses or progresses
Iannitto, E., Mancuso, S., Augello, A., Franco, G., Domingo Domenech, E., Pennese, E., et al. (2010). BENDAMUSTINE IN ASSOCIATION WITH RITUXIMAB AS SALVAGE THERAPY FOR SPLENIC MARGINAL ZONE LYMPHOMA. In 15TH CONGRESS OF THE EUROPEAN HEMATOLOGY ASSOCIATION. Fondaz Ferrata Storti.
BENDAMUSTINE IN ASSOCIATION WITH RITUXIMAB AS SALVAGE THERAPY FOR SPLENIC MARGINAL ZONE LYMPHOMA
MANCUSO, Salvatrice;FRANCO, Giovanni;
2010-01-01
Abstract
At present, a prospectively validated treatment for SMZL is lacking. Despite this fact, splenectomy is still deemed to be the best choice for patients requiring treatment. Nevertheless, the high fraction of patients achieving a clinical response following splenectomy eventually relapses or progresses
File in questo prodotto:
| File | Dimensione | Formato | |
|---|---|---|---|
|
EHA 2010 1287.pdf
Solo gestori archvio
Descrizione: Abstract EHA 2010 1287
Dimensione
72.77 kB
Formato
Adobe PDF
|
72.77 kB | Adobe PDF | Visualizza/Apri Richiedi una copia |
I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.
